Literature DB >> 20450935

Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1.

Yingwei Chen1, Wenxin Luo, Wai Lan Wu, Zhong Fang, Lin Xia, Xun Gui, Yixin Chen, Honglin Chen, J Wai-Kuo Shih, Ningshao Xia.   

Abstract

Hemagglutinin (HA), the major antigen on the surface of influenza viruses, is the primary target for neutralizing antibodies and vaccine design. However, frequent mutations in this gene allow the virus to evade host immune responses and conventional prophylaxis and treatment. In this report, we humanized 4D1 and 10F7 mouse monoclonal antibodies (mAbs) that, we had previously shown to display broad-spectrum neutralization to avian H5N1 virus. The genes of variable (V) regions of 4D1 and 10F7 mAbs were combined with constant region of human antibody to construct the chimeric antibodies (cAbs). The results of hemagglutinin inhibition (HI) and neutralization assays showed that 4D1 and 10F7 cAbs were functional and retained broad-spectrum reactivity. Antibody competitive ELISA and affinity tests indicated that the cAbs recognized the same epitope as the parent mAbs with similar affinity. In animal experiments, the 10F7 cAb showed full protection against lethal challenge of highly virulent avian H5N1 virus, A/BH Goose/QH/15C/2005, in all infected mice. These humanized broad-spectrum antibodies may be potentially important for the control of both current and future antigenic variants of H5N1 virus. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20450935     DOI: 10.1016/j.antiviral.2010.04.012

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  4 in total

1.  Extent of antigenic cross-reactivity among highly pathogenic H5N1 influenza viruses.

Authors:  Mariette F Ducatez; Zhipeng Cai; Malik Peiris; Yi Guan; Zhiping Ye; Xiu-Feng Wan; Richard J Webby
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

2.  Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD).

Authors:  Mirian Mendoza; Angela Ballesteros; Qi Qiu; Luis Pow Sang; Soumya Shashikumar; Sofia Casares; Teodor-D Brumeanu
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

3.  A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.

Authors:  Saori Sakabe; Kiyoko Iwatsuki-Horimoto; Taisuke Horimoto; Chairul A Nidom; Mai thi Quynh Le; Ryo Takano; Ritsuko Kubota-Koketsu; Yoshinobu Okuno; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  Antiviral Res       Date:  2010-09-16       Impact factor: 5.970

4.  An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.

Authors:  Mark Zanin; Zhen-Yong Keck; G Jonah Rainey; Chia-Ying Kao Lam; Adrianus C M Boon; Adam Rubrum; Daniel Darnell; Sook-San Wong; Yolanda Griffin; Jinming Xia; Robert G Webster; Richard Webby; Syd Johnson; Steven Foung
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.